Logo
x

Search

Subscribe Now

sellas

SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)

SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)

  • March 27, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

  • October 14, 2023
SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia

  • October 12, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.